CHRO — Channel Therapeutics Balance Sheet
0.000.00%
Last trade - 00:00- $7.69m
- $9.36m
Annual balance sheet for Channel Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — |
| Source: | PROSPECTUS | PROSPECTUS | PROSPECTUS | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Cash | |||||
| Cash and Short Term Investments | — | — | 0.055 | 0.096 | 0.513 |
| Prepaid Expenses | |||||
| Total Other Current Assets | |||||
| Total Current Assets | 0.072 | 0 | 0.055 | 0.096 | 1.37 |
| Total Assets | 0.072 | 0 | 0.055 | 0.096 | 1.37 |
| Accounts Payable | |||||
| Payable / Accrued | |||||
| Accrued Expenses | |||||
| Notes Payable / Short Term Debt | |||||
| Total Current Liabilities | 3.65 | 2.58 | 3.76 | 6.54 | 4.08 |
| Total Long Term Debt | |||||
| Total Debt | |||||
| Total Other Liabilities | |||||
| Total Liabilities | 3.65 | 3.68 | 3.76 | 6.54 | 4.08 |
| Redeemable Preferred Stock | |||||
| Common Stock | |||||
| Additional Paid In Capital | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Total Equity | -3.58 | -3.68 | -3.71 | -6.44 | -2.71 |
| Total Liabilities & Shareholders' Equity | 0.072 | 0 | 0.055 | 0.096 | 1.37 |
| Total Common Shares Outstanding | |||||
| Total Preferred Shares Outstanding |